CONFERENCE SERIES: Biological Therapeutic Products
Recorded at: PepTalk: The Protein Science Week
Digital Course: Harnessing CHO Cells: The Work Horses Of Bioproduction
About this Product:
Chinese hamster ovary (CHO) cells are the predominant cell factory for the production of biotherapeutics. Nevertheless, even with the recently released CHO cell DNA sequence, more research is required to harness their production potential. This digital short course is designed to provide practical solutions for CHO cell lines including:
- Sequencing and characterization
- Engineering and stability
- Transfection and production
- Culture and media
About this Product:
Over 97 Minutes
Site License: $1380
Agenda At A Glance:
The International Community's Effort to Sequence and Distribute the CHO Genome
Kelvin H. Lee, Ph.D., Gore Professor, Chemical Engineering, Director, DE Biotechnology Institute, University of Delaware
Biography: Kelvin H. Lee is Gore Professor of Chemical Engineering at the University of Delaware and is Director of the Delaware Biotechnology Institute. He has been recognized in a number of ways: DuPont Young Professor award, NSF CAREER award, Cornell’s Menschel Award for Distinguished Scholarship, and the Dreyfus Foundation Teacher-Scholar Award. He has also been recognized by Technology Review as a Top Innovator in Business and Technology and by the journal Metabolic Engineering with the Jay Bailey Best Paper award. He serves as an advisor to a number of small and large biotechnology and pharmaceutical companies. He is a Fellow of the American Institute for Medical and Biological Engineering and a Fellow of the American Association for the Advancement of Science.
Secretory Capacity of CHO Cells is Shaped by the Physicochemical Properties of Individual Secretory Cargo
Haruki Hasegawa, Ph.D., Cell Biologist, Protein Science, Amgen, Inc.
Biography: Haruki is a molecular cell biologist studying the biosynthesis and intracellular trafficking of therapeutically important proteins. Besides the secretory proteins, his interests encompass membrane-anchored proteins and proteins secreted via non-classical pathways as well as the protein recycling events in the endocytic pathways. Haruki received Ph.D. in cell and molecular biology from University of Michigan. He was a post-doctoral fellow at the National Institutes of Health, Bethesda. He spent four years at Bayer to develop cell-based assays for HTS. At Amgen, he is pursuing protein therapeutic discovery. Haruki is also a decent table tennis player and a Shiba-inu enthusiast.
Overexpression of Taurine Transporter in CHO Cells Can Enhance Cell Viability and Product Yield While Promoting Glutamine Consumption
Hisahiro Tabuchi, Ph.D., Chief Scientist, API Process Development (Biotechnology), Pharmaceutical Technology, Chugai Pharmaceutical Co., Ltd.
Biography: Hisahiro Tabuchi is a molecular biologist working for Chugai Pharmaceutical Corporation Co., Ltd., in Tokyo. He has 23 years of experience as a research scientist in The Roche Group. Currently, his particular focus is on cell engineering by introducing target genes. He hopes he will lead the world in intellectual property.
About the Conference:
PepTalk 2012 continues the tradition of strong scientific programming centered around protein-based therapeutics. The four distinct protein pipelines focused on formulation, purification, biotherapeutics and expression range from applying protein discovery research, to developing downstream protein products that ultimately lead to clinical applications. This focused design enables you create your own agenda by moving between the tracks and choosing the sessions that best fit your research and networking needs. Additional networking opportunities will be available through BuzZ Session discussion groups, short courses and panel discussions.